Pfizer to Acquire Arena Pharmaceuticals
December 14, 2021
Arena Pharmaceuticals, Inc. and Pfizer Inc. have entered into a definitive agreement under which Pfizer will acquire Arena. The boards of directors of both companies have unanimously approved the transaction.
The proposed acquisition allows Arena to utilize Pfizer’s established infrastructure across global markets and expertise in Inflammation and Immunology, as well as Cardiology, to accelerate and advance Arena’s pipeline. Arena believes this transaction represents the best next step for the company and will potentially allow them to more rapidly address unmet needs for a broader number of patients with inflammatory and cardiovascular diseases.
The proposed transaction is subject to customary closing conditions, including receipt of regulatory approvals and approval by Arena stockholders. Arena is committed to executing a smooth transition. Between now and the closing date, operations at Arena will not change. Arena will continue to enroll studies and drive forward on our stated timelines.
Read the press release with transaction information here »
Recent News
- bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
- DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY
- 2025 BIO International Recap
- Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
- Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services
- RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS
